US Bancorp
RCUS icon

US Bancorp’s Arcus Biosciences RCUS Stock Holding History

US Bancorp’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$14.2K Buy
459
+56
+14% +$1.38K ﹤0.01% 3345
2026
Q1 		$8.7K Buy
403
+26
+7% +$562 ﹤0.01% 3404
2025
Q4 		$8.98K Hold
377
– – ﹤0.01% 3371
2025
Q3 		$5.13K Sell
377
-17,606
-98% -$183K ﹤0.01% 3527
2025
Q2 		$146K Sell
17,983
-1,773
-9% -$15.1K ﹤0.01% 2219
2025
Q1 		$155K Buy
19,756
+12,869
+187% +$149K ﹤0.01% 2161
2024
Q4 		$103K Buy
6,887
+6,615
+2,432% +$108K ﹤0.01% 2388
2024
Q3 		$4.16K Sell
272
-1,790
-87% -$28.2K ﹤0.01% 3630
2024
Q2 		$31.4K Buy
2,062
+1,353
+191% +$21.8K ﹤0.01% 2878
2024
Q1 		$13.4K Sell
709
-7,952
-92% -$137K ﹤0.01% 3234
2023
Q4 		$165K Buy
8,661
+6,751
+353% +$108K ﹤0.01% 2105
2023
Q3 		$34.3K Sell
1,910
-1
-0.1% -$20 ﹤0.01% 2623
2023
Q2 		$38.8K Buy
1,911
+536
+39% +$10.2K ﹤0.01% 2625
2023
Q1 		$25.1K Buy
1,375
+328
+31% +$6.27K ﹤0.01% 2874
2022
Q4 		$21.7K Buy
1,047
+547
+109% +$15.1K ﹤0.01% 2954
2022
Q3 		$13K Buy
500
+31
+7% +$820 ﹤0.01% 3279
2022
Q2 		$12K Sell
469
-99
-17% -$2.42K ﹤0.01% 3313
2022
Q1 		$18K Buy
568
+277
+95% +$9.28K ﹤0.01% 3143
2021
Q4 		$12K Sell
291
-252
-46% -$9.78K ﹤0.01% 3359
2021
Q3 		$19K Buy
543
+444
+448% +$13.8K ﹤0.01% 3158
2021
Q2 		$3K Hold
99
– – ﹤0.01% 3756
2021
Q1 		$3K Hold
99
– – ﹤0.01% 3632
2020
Q4 		$3K Buy
+99
New +$2.4K ﹤0.01% 3514
2020
Q3 		– Sell
-44
Closed -$1K – 3821
2020
Q2 		$1K Buy
+44
New +$1.19K ﹤0.01% 3643
2019
Q3 		– Sell
-2,891
Closed -$23K – 3657
2019
Q2 		$23K Hold
2,891
– – ﹤0.01% 2825
2019
Q1 		$36K Buy
2,891
+645
+29% +$7K ﹤0.01% 2637
2018
Q4 		$25K Buy
2,246
+120
+6% +$1.4K ﹤0.01% 2730
2018
Q3 		$30K Buy
+2,126
New +$27.1K ﹤0.01% 2784

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

US Bancorp's RCUS Position: Q2 2026 in Review

US Bancorp increased its Arcus Biosciences (RCUS) stake by 14% in Q2 2026, buying an estimated $1.38K and bringing the position to 459 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3345.

US Bancorp first reported a position in RCUS in Q3 2018 and has held it in 28 quarters since. The position peaked at $165K in Q4 2023. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • US Bancorp held 459 shares of Arcus Biosciences worth $14.2K as of Q2 2026.
  • US Bancorp bought 56 Arcus Biosciences shares in Q2 2026, an estimated $1.38K.
  • Arcus Biosciences made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3345 holding.
  • US Bancorp first reported a position in Arcus Biosciences in Q3 2018 and has held it in 28 quarters since.
  • US Bancorp's Arcus Biosciences position peaked at $165K in Q4 2023.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.